Financial Performance - The company's operating revenue for Q3 2022 was ¥4,876,888,188.45, representing a 10.53% increase year-over-year[6]. - Net profit attributable to shareholders for Q3 2022 reached ¥355,439,234.76, a significant increase of 181.85% compared to the same period last year[6]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥362,232,096.57, up 183.93% year-over-year[6]. - Basic earnings per share for Q3 2022 were ¥0.26, reflecting a 165.00% increase from ¥0.19 in the same quarter last year[6]. - The company's net profit attributable to shareholders rose to ¥2.48 billion, compared to ¥2.22 billion in the previous year, an increase of approximately 11.7%[27]. - Basic earnings per share for the current period is 0.19, compared to -0.18 in the previous period[33]. - The total comprehensive income attributable to shareholders of the parent company is 245,186,269.12, while the previous period showed a loss of 158,326,403.58[33]. Assets and Liabilities - Total assets at the end of Q3 2022 amounted to ¥18,963,552,324.99, marking a 10.35% increase from the end of the previous year[6]. - Total assets increased to ¥18.96 billion as of September 30, 2022, compared to ¥17.18 billion at the beginning of the year, reflecting a growth of approximately 10.4%[27]. - The total liabilities decreased to ¥9.31 billion from ¥9.40 billion, a decline of approximately 0.9%[27]. - The equity attributable to shareholders increased to ¥7.89 billion from ¥7.15 billion, reflecting a growth of about 10.3%[27]. Cash Flow - Cash flow from operating activities for the year-to-date was ¥1,833,785,122.11, down 49.47% compared to the same period last year[13]. - The net cash flow from operating activities decreased to 1,833,785,122.11 from 3,629,302,404.17 in the previous period[37]. - The net cash flow from financing activities was ¥1,443,593,555.22, a 192.00% increase, primarily due to increased investments from shareholders[13]. - The net cash flow from financing activities is 1,443,593,555.22, a significant improvement from -1,569,136,550.80 in the previous period[40]. - The total cash and cash equivalents at the end of the period is 5,811,695,832.70, up from 2,767,644,090.16 in the previous period[40]. Investments and Shareholding - The company reported a total of 283,929,184 shares held by its largest shareholder, Xinjiang Production and Construction Corps State-owned Assets Management Co., Ltd., representing a significant portion of ownership[17]. - Xinjiang Tianbang Hongkang Venture Capital Partnership holds 62,580,733 shares, accounting for 4.62% of the total shares[17]. - The company has initiated a mixed-ownership reform plan for Tiankang Pharmaceutical (Suzhou) Co., Ltd., approved by the board on June 1, 2022, to attract external strategic investors and employee shareholding[20]. - The share price for the external strategic investment in Tiankang Pharmaceutical was set at 15.81 yuan per unit of registered capital during the public solicitation process[21]. - As of September 25, 2022, all new shareholders of Tiankang Pharmaceutical have completed their capital contributions[21]. - The company is actively expanding its market presence through strategic partnerships and investments in Tiankang Pharmaceutical[20]. - The top ten shareholders collectively hold a significant portion of the company's shares, with the largest shareholder having no related party relationships with others[17]. - The company is focused on enhancing its capital structure through the introduction of new investors and employee ownership initiatives[20]. Research and Development - Research and development expenses increased by 72.71% to ¥50,492,134.33, indicating a focus on innovation[13]. - Research and development expenses for the quarter were ¥122.35 million, up from ¥103.20 million, indicating an increase of about 18.5%[30]. Other Financial Metrics - The company's cash and cash equivalents increased to ¥5.92 billion from ¥3.42 billion, marking a significant growth of about 73.1%[24]. - Inventory decreased to ¥3.93 billion from ¥5.23 billion, a reduction of approximately 24.8%[24]. - Long-term borrowings increased to ¥2.89 billion from ¥1.96 billion, reflecting a growth of about 47.3%[27]. - The company's long-term borrowings rose by 47.06% to ¥2,888,269,363.22, reflecting adjustments in loan structure[13]. - The total profit for the current period is 217,953,683.97, compared to a loss of 57,757,472.82 in the previous period[33]. - The net profit attributable to shareholders of the parent company is 257,958,881.22, while the previous period showed a loss of 192,859,153.56[33]. - The net cash flow from investing activities is -777,460,915.19, compared to -1,242,949,423.18 in the previous period[40]. - The company reported a decrease in other comprehensive income, with a net amount of -12,772,612.10 compared to 34,532,749.98 in the previous period[33].

Financial Performance - The company's operating revenue for the first half of 2022 was ¥8,008,625,554.64, representing a 1.16% increase compared to ¥7,916,638,583.45 in the same period last year[27]. - The net profit attributable to shareholders of the listed company was -¥97,480,353.54, a decrease of 140.38% from ¥241,396,816.85 in the previous year[27]. - The net cash flow from operating activities was ¥389,762,424.56, down 86.59% from ¥2,907,019,096.74 in the same period last year[27]. - The basic earnings per share were -¥0.07, a decline of 131.82% compared to ¥0.22 in the previous year[27]. - Total assets at the end of the reporting period were ¥16,228,737,642.33, a decrease of 5.56% from ¥17,184,738,668.37 at the end of the previous year[27]. - The net assets attributable to shareholders of the listed company were ¥7,026,317,148.09, down 1.71% from ¥7,148,418,633.08 at the end of the previous year[27]. Operational Challenges - The company reported a significant decrease in net profit due to various operational challenges faced during the reporting period[27]. - The company faced challenges in achieving expected benefits due to low pork prices influenced by domestic market conditions[73]. - The company has faced challenges in project profitability due to the impact of African swine fever and fluctuating market conditions[92]. Strategic Focus - The company is focusing on improving its operational efficiency and exploring new market opportunities to enhance future performance[27]. - The management has outlined strategies to mitigate risks and adapt to market changes in the upcoming periods[27]. - The company plans to gradually expand the "company + farmers" breeding model as its pig farming scale increases[48]. - The company has identified opportunities for large-scale breeding enterprises to expand their scale due to the exit of many small and medium-sized farmers from the market[92]. Revenue Breakdown - The company sold 109.74 million tons of feed, a year-on-year decrease of 2.90%, with sales revenue of 275,183.27 million yuan, an increase of 6.35%[45]. - The company reported a sales revenue of 220,380.27 million yuan from pig farming, a year-on-year increase of 29.75%, with 931,500 pigs sold, a year-on-year increase of 26.53%[47]. - The company's plant protein and oil processing business generated sales revenue of 102,484.06 million yuan, a year-on-year increase of 17.83%[47]. - The company's corn storage business saw a sales revenue of 128,633.18 million yuan, a year-on-year decrease of 38.68%[47]. - The overall gross margin for the company's main business was 6.82%, a decrease of 9.09 percentage points year-on-year[47]. Investment and Assets - The company invested over ¥200 million in the construction of a high-level biosafety laboratory (P3), which was completed and put into use in 2020[51]. - The company achieved a net cash flow from operating activities of ¥389,762,424.56, a decrease of 86.59% compared to ¥2,907,019,096.74 in the previous year[55]. - The company reported a significant increase in fixed assets, which rose to 4.899 billion, accounting for 30.19% of total assets[63]. - The company has invested a total of 98,550 million CNY through convertible bonds, with 1,606.32 million CNY utilized in the current period and a cumulative usage of 81,253.92 million CNY[84]. Environmental Compliance - The company reported a total wastewater discharge of 1.82 tons of ammonia nitrogen and 16.4 tons of chemical oxygen demand (COD) annually, which is within the permitted limits[128]. - The company has installed a low-nitrogen natural gas boiler with a capacity of 10 tons and 6 tons, which has been operational since October 2020, ensuring nitrogen oxide emissions are compliant with standards[128]. - The company has established an emergency response plan for environmental incidents, with a command center led by the general manager[137]. - The company has implemented measures to prevent environmental pollution incidents, ensuring the safety of the environment and public health[138]. Corporate Governance - The company has established a governance structure that ensures the protection of shareholder and creditor rights[152]. - The company has not experienced any changes in its board of directors, supervisors, or senior management during the reporting period[114]. - The company has committed to distributing at least 10% of its distributable profits in cash dividends annually for the next three years, with potential increases if net profits continue to grow[159]. Related Party Transactions - The company reported a total of 632,000 RMB in related party transactions, accounting for 12.97% of similar transaction amounts[168]. - The approved transaction amount for related party transactions was 1,400,000 RMB, with no transactions exceeding this limit[168]. - The company has not provided any guarantees to related parties during the reporting period[182].

二○二二年六月十七日 | --- | --- | --- | --- | |--------------------------------|--------------------------|----------------------------------------------------------------|--------------------------------------------------------------------------| | | | | | | 证券代码： | 002100 | 证券简称：天康生物 | | | 债券代码： | 128030 | 债券简称：天康转债 | 公告编号： 2022-044 | | | | 天康生物股份有限公司 | | | | | 关于参加 2022 | 年新疆辖区投资者 | | | | 网上集体接待日暨上市公司业绩说明会活动的公告 | | | | | | 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 | | 记载、误导性陈述或者重大遗漏。 | | | | | | | | 为便于广大投资者更深入全面地了解公司情况、 ...

Financial Performance - The company's revenue for Q1 2022 was ¥3,391,929,405.09, representing a 1.58% increase compared to ¥3,339,230,680.67 in the same period last year[4] - The net profit attributable to shareholders was -¥69,605,796.25, a decrease of 123.12% from ¥301,009,811.74 in the previous year[4] - The net cash flow from operating activities was -¥808,347,021.44, a decline of 238.17% compared to ¥585,028,585.93 in Q1 2021[4] - The company's total equity decreased from ¥7,783,303,372.25 to ¥7,603,798,910.94, representing a decrease of approximately 2.3%[23] - The net profit for the current period was a loss of CNY 108,566,710.19, compared to a profit of CNY 312,204,675.61 in the previous period, indicating a substantial decline[27] - The company reported a basic and diluted earnings per share of -0.05, down from 0.28 in the previous period[30] - The total comprehensive income for the current period was a loss of CNY 188,142,159.14, compared to a comprehensive income of CNY 312,204,675.61 in the previous period[30] Cash Flow - The company's cash and cash equivalents decreased from ¥3,424,083,819.49 at the beginning of the year to ¥2,322,436,762.83, representing a decline of approximately 32.3%[14] - Cash inflow from operating activities totaled CNY 3,162,894,211.54, a decrease from CNY 3,524,356,259.57 in the previous period[31] - The net cash flow from operating activities was -$808,347,021.44, a decrease from $585,028,585.93 in the previous period[34] - Cash outflow from operating activities totaled $3,971,241,232.98, compared to $2,939,327,673.64 previously[34] - The ending cash and cash equivalents balance was $2,175,960,504.84, up from $1,732,129,657.41 at the beginning of the period[37] Assets and Liabilities - The total assets at the end of the reporting period were ¥17,090,267,464.43, a decrease of 0.55% from ¥17,184,738,668.37 at the end of the previous year[4] - Accounts receivable increased significantly from ¥323,390,791.30 to ¥562,498,770.36, marking an increase of about 74%[17] - Inventory rose from ¥5,231,785,064.81 to ¥5,811,482,596.45, indicating an increase of approximately 11%[17] - Current liabilities decreased from ¥6,956,371,740.34 to ¥6,720,954,878.66, a reduction of about 3.4%[20] - Long-term borrowings increased from ¥1,964,000,000.00 to ¥2,254,000,000.00, reflecting a growth of approximately 14.7%[20] - The total liabilities increased from ¥9,401,435,296.12 to ¥9,486,468,553.49, an increase of about 0.9%[20] Expenses - Research and development expenses increased by 44.43% to ¥38,129,010.71 from ¥26,399,254.36 in the same period last year[6] - Total operating costs increased significantly to CNY 3,497,856,389.13 from CNY 2,991,259,996.71, marking an increase of about 17%[24] - The company experienced a significant increase in sales expenses, which rose to CNY 102,896,660.62 from CNY 87,342,342.14, an increase of approximately 17.5%[24] - The company reported a decrease in tax expenses to CNY 10,771,066.79 from CNY 13,843,938.13, a reduction of about 22.5%[27] Investment and Financing - The company received government subsidies amounting to ¥7,234,780.66, an increase of 25.47% from ¥5,766,068.36 in the same period last year[6] - The company’s investment income decreased by 54.58% to ¥8,040,381.48 from ¥17,701,587.34 in the previous year[6] - Cash inflow from financing activities was $1,021,500,000.00, an increase from $985,000,000.00 in the prior period[34] - Cash outflow from financing activities amounted to $1,144,078,555.00, down from $1,568,151,019.49 previously[34] - The company incurred tax payments of $21,987,065.28, a decrease from $41,290,626.14 in the prior period[34] - The company reported cash outflow for fixed assets and intangible assets acquisition at $127,769,859.28, down from $198,136,050.00[34]

Financial Performance - In 2021, TianKang Bio experienced significant losses in its pig farming business due to a sharp decline in domestic pig sales prices, marking the company's first loss in over 20 years[5]. - The company's operating revenue for 2021 was ¥15,744,337,617.02, representing a 31.35% increase compared to ¥11,986,808,944.23 in 2020[34]. - The net profit attributable to shareholders for 2021 was -¥685,964,477.34, a decrease of 139.87% from ¥1,720,414,461.95 in 2020[34]. - The net cash flow from operating activities improved significantly to ¥1,532,960,475.93, compared to -¥600,857,389.57 in 2020, marking a 355.13% increase[34]. - The total assets at the end of 2021 were ¥17,184,738,668.37, which is a 9.25% increase from ¥15,729,293,585.91 at the end of 2020[34]. - The company reported a basic earnings per share of -¥0.62 for 2021, down 138.51% from ¥1.61 in 2020[34]. - The weighted average return on equity for 2021 was -11.75%, a decline of 43.61% from 31.86% in 2020[34]. - The company reported a net profit attributable to shareholders of CNY -68,596.45 million, a decline of 139.87% compared to the previous year[68]. Business Strategy and Operations - The company aims to stabilize its pig farming scale at 5 million heads, focusing on healthy and high-quality development[5]. - The overall strategy for 2022 includes maintaining a complete industry chain and focusing on high-quality development amidst the challenges of the "pig cycle"[5]. - The company plans to explore futures hedging with a target amount of 1 billion RMB in 2022 to mitigate risks associated with falling pig prices[6]. - The company will implement a cost reduction strategy by establishing a cost big data analysis and early warning platform to identify and control cost points[6]. - The management emphasizes the importance of learning from the experiences of 2021 to navigate future opportunities and challenges[7]. - The company aims to achieve a feed production and sales volume of 3 million tons, with a target of 220,000 pigs slaughtered and 1.989 billion yuan in total revenue for 2022[177]. - The company will focus on a full-cost leadership strategy in its feed business, ensuring efficiency across procurement, production, logistics, and human resources[178]. Research and Development - TianKang Bio will enhance research and development efforts in feed and breeding technology to further reduce costs[6]. - The company has committed to not distributing cash dividends or bonus shares for the year[12]. - The company has developed a vaccine for porcine reproductive and respiratory syndrome (PRRS) that requires only a single injection, reducing labor and stress on pigs, which is expected to positively impact performance[1]. - The company has obtained new veterinary drug registration certificates for multiple vaccines, including those for porcine pleuropneumonia and foot-and-mouth disease, enhancing its product portfolio[1]. - The company aims to enhance its market competitiveness by diversifying its vaccine product line with the successful development of new vaccines[96]. - The company achieved a research and development investment of ¥142,889,664.78 in 2021, representing a 37.41% increase from ¥103,986,145.98 in 2020[108]. - The proportion of R&D investment to operating revenue increased to 0.91% in 2021 from 0.87% in 2020, showing a slight growth of 0.04%[108]. Market and Industry Trends - In 2021, China's pork production reached 52.96 million tons, an increase of 28.8% year-on-year, with a total of 671.28 million pigs slaughtered, up 27.4% from the previous year[171]. - By the end of 2021, the national pig stock was 449.22 million heads, and the breeding sow stock was 43.29 million heads, representing growth of 10.5% and 4.0% respectively compared to the end of 2020[171]. - The agricultural policy aims to stabilize pork production capacity at around 55 million tons and maintain a self-sufficiency rate of approximately 95% for pork[173]. - The company recognizes the increasing market concentration in the feed industry and aims to leverage its core competencies to thrive amid challenges[170]. Risk Management and Compliance - The company has established a robust biosecurity management system for pig farming to mitigate the risks associated with African swine fever, which remains a significant threat since the first case was reported in August 2018[185]. - The company has strengthened its internal control systems and governance structures in compliance with relevant laws and regulations, ensuring operational transparency[194]. - The board of directors consists of nine members, including three independent directors, ensuring compliance with governance standards[197]. - The company has maintained fair and reasonable related-party transactions with its controlling shareholder, ensuring independence in operations and decision-making[196]. Investment and Financing - The company raised 2.066 billion RMB through a private placement at the end of 2021 and plans to apply for a bank financing limit of 9.61 billion RMB in 2022 to maintain stable cash flow[6]. - The total investment amount for the reporting period was ¥1,790,315,527.80, representing a 91.43% increase from the previous year's investment of ¥935,224,113.03[118]. - The company has established a professional futures team to monitor market price trends and control futures positions[128]. - The company has completed the replacement of 38,797.86 million yuan of self-raised funds with raised funds for investment projects[144].

Financial Performance - The company's operating revenue for Q3 2021 was ¥4,412,241,435.12, representing a 12.63% increase year-over-year, while the total revenue for the year-to-date reached ¥12,328,880,018.57, up 43.01% compared to the same period last year[5] - The net profit attributable to shareholders for Q3 2021 was -¥434,255,970.41, a decrease of 167.45% year-over-year, with a year-to-date net profit of -¥192,859,153.56, down 113.05% compared to the previous year[5] - The total operating revenue for the third quarter reached ¥12,328,880,018.57, an increase of 43.5% compared to ¥8,620,752,350.59 in the same period last year[37] - The company reported a total operating profit (loss) of -36,727,106.21, a stark contrast to the previous operating profit of 1,540,695,224.14[40] - The net profit for the current period is -101,197,342.94, compared to a net profit of 1,514,841,362.12 in the previous period, indicating a significant decline[40] - The total comprehensive income attributable to the parent company owner was -158,326,403.58, compared to 1,477,586,003.68 in the previous period[43] - The basic earnings per share for the current period is -0.18, compared to 1.38 in the previous period, reflecting a decline in profitability[43] Cash Flow and Investments - The net cash flow from operating activities for the year-to-date was ¥3,629,302,404.17, reflecting a 73.01% increase compared to the same period last year[5] - The cash flow from operating activities netted 3,629,302,404.17, compared to 2,097,715,885.13 in the previous period, representing an increase of approximately 73.1%[44] - The company’s cash flow from investing activities showed a net outflow of -¥1,242,949,423.18, which was a 238.75% increase in outflow compared to the previous year[12] - The net cash flow from investing activities was -$1.24 billion, compared to -$366.92 million in the previous period[50] - The net cash flow from financing activities was -$1.57 billion, an increase from -$996.88 million year-over-year[50] Assets and Liabilities - Total assets at the end of Q3 2021 were ¥14,125,593,187.89, a decrease of 10.20% from the end of the previous year, while total equity attributable to shareholders was ¥5,633,414,175.65, down 9.63%[7] - The total assets increased to $15.87 billion, reflecting an adjustment of $142.70 million due to the new leasing standards[61] - The total liabilities rose to $9.00 billion, with a notable increase in non-current liabilities by $142.70 million[61] - Total liabilities decreased to ¥7,737,927,143.58 from ¥8,861,606,062.86, a reduction of 12.7%[35] - Shareholders' equity totaled ¥6,387,666,044.31, down from ¥6,867,687,523.05, reflecting a decrease of 7.0%[35] Shareholder Information - The total number of common shareholders at the end of the reporting period was 96,197[17] - The largest shareholder, Xinjiang Production and Construction Corps State-owned Assets Management Co., Ltd., holds 26.38% of shares, totaling 283,929,184 shares[17] - Beijing Rongyuan Baotong Asset Management Partnership holds 6.39% of shares, totaling 68,754,835 shares, with 10,669,513 shares frozen[17] - Xinjiang Tianbang Hongkang Venture Capital Partnership holds 5.81% of shares, totaling 62,580,733 shares[17] - Xinjiang Tianbang Hongkang Venture Capital Partnership holds 20,000,000 shares through a credit securities account[20] - He Sheng holds 4,700,000 shares through a credit securities account[20] Operational Metrics - The company reported a significant increase in accounts receivable, which rose by 72.87% to ¥552,992,588.27, attributed to expanded sales[10] - The company’s inventory decreased by 50.09% to ¥3,004,604,027.87, mainly due to seasonal sales patterns in agricultural products[13] - Total operating costs amounted to ¥12,249,517,556.23, up from ¥7,034,827,366.08, reflecting a significant increase in operational expenses[37] - Cash and cash equivalents increased to ¥3,011,280,484.53 from ¥2,067,234,276.03, representing a growth of 45.5% year-over-year[31] - Accounts receivable rose to ¥552,992,588.27, compared to ¥319,881,376.70, indicating a 72.8% increase[31] - Inventory decreased to ¥3,004,604,027.87 from ¥6,020,026,015.04, a decline of 50.2%[31] - Non-current assets totaled ¥6,170,481,378.89, up from ¥5,032,416,026.65, marking a growth of 22.6%[32] Expenses - The company’s management expenses increased by 44.15% to ¥585,539,002.30, driven by expanded operations and increased share-based payment amortization[12] - The company incurred financial expenses of 149,251,162.29, up from 124,754,901.05, indicating increased borrowing costs[40] - The company’s total tax expenses were 43,439,870.12, compared to 25,404,126.94 in the previous period, indicating higher tax liabilities[40] - Research and development expenses increased slightly to 103,198,682.12 from 102,620,466.88, showing a focus on innovation[40] Stock Issuance - The company received approval for a non-public stock issuance from the Xinjiang Production and Construction Corps State-owned Assets Supervision and Administration Commission on January 18, 2021[21] - The company’s non-public stock issuance application was accepted by the China Securities Regulatory Commission on February 22, 2021[22] - The non-public stock issuance application was approved by the China Securities Regulatory Commission on May 10, 2021[24] - The employee stock ownership plan's lock-up period expired on September 14, 2021, allowing for the release of shares[25] Market Strategy - The company is focusing on expanding its market presence and developing new products to drive future growth[39]

Financial Performance - The company's operating revenue for the first half of 2021 was ¥7,916,638,583.45, representing a 68.32% increase compared to ¥4,703,279,226.34 in the same period last year[27]. - The net profit attributable to shareholders of the listed company decreased by 71.05% to ¥241,396,816.85 from ¥833,796,729.94 in the previous year[27]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥263,802,491.88, down 69.19% from ¥856,324,136.19 year-on-year[27]. - Basic earnings per share were ¥0.22, a decrease of 71.79% from ¥0.78 in the previous year[27]. - The company reported a significant decline in net profit attributable to shareholders, which was CNY 24,139.68 million, down 71.05% year-on-year[43]. - The company’s total profit decreased by 58.85% year-on-year, amounting to CNY 34,088.07 million[43]. Cash Flow and Assets - The net cash flow from operating activities increased by 137.66% to ¥2,907,019,096.74, compared to ¥1,223,192,384.23 in the same period last year[27]. - The company reported a net cash flow from operating activities of CNY 2,907,019,096.74, an increase of 137.66% year-on-year[50]. - Total assets at the end of the reporting period were ¥14,288,854,416.64, down 9.16% from ¥15,729,293,585.91 at the end of the previous year[27]. - The company’s cash and cash equivalents at the end of the reporting period were ¥1,782,457,686.98, down 0.67% from ¥2,067,234,276.03 at the end of the previous year[61]. - The company’s inventory amounted to ¥4,778,543,861.47, representing 33.44% of total assets, with a notable increase in sales of agricultural products[61]. Revenue Breakdown - The company achieved total operating revenue of CNY 791,663.86 million, a year-on-year increase of 68.32%[43]. - The company's feed business saw sales revenue of CNY 258,744.37 million, up 33.64% year-on-year, with sales volume increasing by 40.72% to 1.13 million tons[43]. - The company experienced a 32.71% increase in sales revenue from its pig farming business, totaling CNY 169,854.71 million, with pig sales volume rising by 73.18% to 736,200 heads[44]. - The corn storage industry saw a remarkable revenue increase of 411.14%, with current revenue at ¥2,097,709,983.03 compared to ¥410,397,105.73 last year[54]. - Revenue from the livestock breeding sector was ¥999,138,462.81, reflecting a 22.94% increase from ¥812,732,016.86 in the previous year[54]. Investment and R&D - The company’s R&D investment increased by 8.93% to CNY 63,474,905.90, reflecting its commitment to innovation[50]. - The company reported an investment amount of ¥1,015,539,562.90 for the current period, representing a 230.51% increase compared to ¥307,268,547.97 in the same period last year[66]. - The company invested over CNY 200 million in a high-level biosafety laboratory (P3) that has been completed and put into use[49]. Environmental and Social Responsibility - The company has established a robust biosecurity management system to mitigate risks associated with African swine fever, enhancing operational resilience[85]. - The company has implemented the HACCP management system to ensure food safety and maintain product quality standards[86]. - The company donated a total of 1.06 million milliliters of anthrax spore vaccine, 2 million milliliters of porcine epidemic diarrhea virus E2 protein recombinant inactivated vaccine, and 1 million milliliters of Mycoplasma pneumoniae inactivated vaccine, valued at 12.53 million yuan, for disaster relief efforts in Henan Province[118]. - The company emphasizes environmental protection and energy conservation, achieving good results in both environmental protection and cost savings through optimized energy-saving facilities[118]. Corporate Governance - The company has established a comprehensive governance structure, including a shareholders' meeting, board of directors, supervisory board, and management team, ensuring clear responsibilities and mutual coordination[115]. - The company has implemented a robust investor relations management system, ensuring fair treatment of all shareholders and transparent information disclosure[115]. - The company held four shareholder meetings during the reporting period, with investor participation rates of 39.02%, 37.02%, 37.06%, and 37.42% respectively[90]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 98,385, with significant shareholders including Xinjiang Production and Construction Corps holding 26.38%[181]. - The largest shareholder, Xinjiang Production and Construction Corps, held 283,929,184 shares, representing 26.38% of the total shares[189]. - The company reported no new strategic investors or significant changes in shareholder relationships during the period[184]. - The total number of shares at the end of the reporting period was 1,076,289,704, with 100% being unrestricted shares[178]. Guarantees and Financial Commitments - The company has engaged in multiple guarantees with a focus on agricultural and food-related companies, indicating a strategic emphasis on this sector[150][152]. - The total guarantee amount approved during the reporting period was CNY 45,400,000, with actual guarantees amounting to CNY 452,397,000[162]. - The actual guarantee amount accounted for 22.03% of the company's net assets[162]. - The company has not engaged in related party guarantees, suggesting a focus on independent financial transactions[150][152].

天康生物 | --- | --- | --- | --- | |-----------------------------------------------------|--------------------------|--------------------------------------------------------------------------|------------------------------------------| | | | | | | 证券代码： | 002100 | 证券简称：天康生物 | | | 债券代码： | 128030 | 债券简称：天康转债 | 公告编号： 2021-045 | | | | 天康生物股份有限公司 | | | | 关于参加 | 2021 年新疆辖区投资者网上集体接待日 | | | | | 暨上市公司业绩说明会活动的公告 | | | | | 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 | | | 记载、误导性陈述或者重大遗漏。 | | | | | | | 为便于广大投资者更深入全面地了解公司情况、发展战略、经营状况 ...

Financial Performance - The company's operating revenue for Q1 2021 was ¥3,339,230,680.67, representing a 68.35% increase compared to ¥1,983,537,035.47 in the same period last year[10] - The net profit attributable to shareholders for Q1 2021 was ¥301,009,811.74, a decrease of 10.03% from ¥334,552,715.62 in the previous year[10] - The basic earnings per share for Q1 2021 was ¥0.28, down 9.68% from ¥0.31 in the previous year[10] - Total revenue for Q1 2021 reached ¥3,339,230,680.67, a 68.35% increase compared to ¥1,983,537,035.47 in Q1 2020[26] - The company reported a net profit of ¥3,752,507,965.00 in retained earnings, an increase from ¥3,451,498,153.26[87] - The company reported a basic earnings per share of CNY 0.28, down from CNY 0.31 in the previous period[104] - Total comprehensive income for the current period is CNY 312,204,675.61, compared to CNY 325,628,705.24 in the previous period[105] Cash Flow - The net cash flow from operating activities increased by 14.57% to ¥585,028,585.93, compared to ¥510,611,919.66 in the same period last year[10] - Cash inflow from sales of goods and services reached ¥3,460,169,194.57, compared to ¥1,948,361,985.47 in the previous period, reflecting a significant increase of about 77.4%[113] - The net cash flow from operating activities was ¥585,028,585.93, up from ¥510,611,919.66 in the previous period, indicating a growth of approximately 14.5%[117] - The cash outflow for operating activities totaled ¥2,939,327,673.64, which is an increase from ¥1,578,966,528.20 in the previous period[117] - The net cash flow from financing activities was -¥583,151,019.49, worsening from -¥208,493,509.37 in the previous period[120] - The cash and cash equivalents at the end of the period were ¥1,732,129,657.41, down from ¥2,140,851,075.19 in the previous period, a decrease of approximately 19.0%[120] Assets and Liabilities - The total assets at the end of the reporting period were ¥15,942,521,786.11, a 1.36% increase from ¥15,729,293,585.91 at the end of the previous year[10] - The company's total current assets as of March 31, 2021, amounted to CNY 10.55 billion, a decrease from CNY 10.70 billion as of December 31, 2020[78] - The total liabilities decreased from CNY 4.76 billion to CNY 3.65 billion in the short-term borrowings category[81] - The company's fixed assets increased to CNY 3.87 billion from CNY 3.67 billion year-over-year[81] - The total assets of the company as of March 31, 2021, amounted to ¥8,034,771,704.95, up from ¥6,776,261,850.26 at the end of the previous year[94] - The total liabilities decreased to ¥3,770,170,582.67 from ¥3,004,931,418.58, indicating a reduction in financial obligations[94] - The company’s total current liabilities increased to ¥2,271,306,906.43 from ¥1,656,802,618.30, indicating a rise in short-term financial obligations[93] Investments and Financing - The company reported a total fundraising amount of RMB 1,000,000,000 from the issuance of 10 million convertible bonds, with a net amount of RMB 981,550,400 after deducting fees[63] - The company received ¥985,000,000.00 in borrowings during the current period, a significant increase from ¥20,000,000.00 in the previous period[120] - The company’s investment activities generated a cash outflow of ¥220,175,569.00, a 1065.11% increase, mainly due to larger investments in feed and breeding businesses[28] - The total cash outflow for investment activities was ¥220,175,569.00, compared to ¥97,475,700.00 in the previous period, indicating a substantial increase in investment expenditures[117] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 102,937[15] - The company’s equity attributable to shareholders increased to ¥4,264,601,122.28, compared to ¥3,771,330,431.68 in the previous year[94] - The company’s total equity increased to ¥7,214,422,701.14 from ¥6,867,687,523.05, reflecting a positive trend in shareholder value[87] Operational Costs and Expenses - Operating costs rose by 87.73% to ¥2,566,093,399.28, attributed to increased sales volume and cost recognition[26] - Sales expenses increased by 121.39% to ¥152,881,230.63, reflecting higher sales and transportation costs due to expanded sales activities[26] - The company reported a 161.50% increase in income tax expenses to ¥13,843,938.13, due to a higher tax rate for the newly established pharmaceutical company[26] - The company recorded a tax expense of CNY 13,843,938.13, up from CNY 5,294,011.26 in the previous period[102] Risk Management and Compliance - The company has implemented strict internal controls and risk management measures for its futures trading activities[42] - The company has not engaged in any entrusted financial management during the reporting period[70] - There were no violations regarding external guarantees during the reporting period[71] - The company has not reported any litigation related to its derivative investments[39]

Financial Performance - In 2020, TianKang Bio achieved a total revenue of 11.987 billion RMB and a profit of 1.72 billion RMB, exceeding the strategic goals set for 2018-2020[4] - The company's operating revenue for 2020 was ¥11,986,808,944.23, representing a 60.33% increase compared to ¥7,476,316,392.02 in 2019[36] - The net profit attributable to shareholders for 2020 was ¥1,720,414,461.95, a significant increase of 166.94% from ¥644,486,713.22 in 2019[36] - The basic earnings per share for 2020 was ¥1.61, up 168.33% from ¥0.60 in 2019[36] - The total assets at the end of 2020 were ¥15,729,293,585.91, which is a 41.01% increase from ¥11,154,464,066.40 at the end of 2019[36] - The company reported a weighted average return on equity of 31.86% for 2020, an increase of 15.03% from 16.83% in 2019[36] - The revenue for the fourth quarter of 2020 was ¥3,366,056,593.64, with a net profit attributable to shareholders of ¥242,828,458.27[41] - The company reported a significant increase in net profit after deducting non-recurring gains and losses, reaching ¥1,727,832,489.76 in 2020, up 171.67% from ¥636,015,341.32 in 2019[36] Business Segments - The pharmaceutical business saw significant growth, with over 100 million RMB invested in R&D in 2020 alone, contributing to the development of 5 new veterinary drug certificates and 51 authorized patents over three years[5] - The feed business grew by 43.83% in 2020, with the Northwest region experiencing a remarkable growth of 54%[7] - The food breeding business successfully increased pig output and profitability despite challenges from dual epidemics, focusing on innovative business models[7] - The agricultural products segment established strategic partnerships with leading corn processing companies, achieving revenue growth while ensuring feed and breeding business needs[8] - The feed business targets a production and sales volume of 5 million tons, with projected revenue of 13 billion RMB and a profit of 400 million RMB[9] - The protein and oil business is projected to process 500,000 tons of cottonseed, generating 1 billion RMB in revenue and 50 million RMB in profit[12] Strategic Goals - The new three-year strategic plan (2021-2023) aims for overall revenue exceeding 30 billion RMB and a profit total of 3 billion RMB by the end of 2023[9] - The company aims to become a leading health farming service provider and safe food supplier in China, achieving a complete industrial chain from breeding to processing and sales, including animal vaccines, feed, and meat products[49] Research and Development - The company invested over CNY 200 million in a high-level biosafety laboratory (P3) completed in 2020[63] - The company has established two R&D centers in Xinjiang and Shanghai, employing nearly 200 specialized R&D personnel[63] - The company has obtained 18 national new veterinary drug certificates and over 60 patents, showcasing its strong R&D capabilities[63] - The company is developing a dual-inactivated vaccine for porcine circovirus type 2 and Mycoplasma pneumonia, which is expected to enhance immunity and reduce stress during vaccination[90] - The company is also working on a genetically engineered subunit vaccine for porcine pleuropneumonia, which has shown effective immunity for up to six months[90] - A bivalent synthetic peptide vaccine for foot-and-mouth disease has been developed, demonstrating good safety and stable immune response[90] Cash Flow and Investments - The net cash flow from operating activities for 2020 was negative at -¥600,857,389.57, a decline of 295.73% compared to ¥306,979,542.98 in 2019[36] - Operating cash inflow totaled ¥12,540,633,977.48 in 2020, a 61.26% increase from ¥7,776,773,079.95 in 2019[98] - Operating cash outflow increased to ¥13,141,491,367.05 in 2020, a 75.93% rise from ¥7,469,793,536.97 in 2019[98] - The company has ongoing significant non-equity investments, including ¥75,739,644.03 in a veterinary drug project, with a completion rate of 89.46%[110] Market Trends and Challenges - The animal vaccine industry is expected to grow due to stricter regulations and the transition to a "no antibiotic" era in livestock farming, which will increase the market share for bacterial vaccines[146] - The company anticipates opportunities in the market for multi-valent and multi-combined vaccines as the industry shifts towards these products[146] - The company aims to leverage the increasing emphasis on disease prevention in livestock farming to drive future growth in its veterinary drug sales[146] - The company has faced challenges in project completion due to the impact of African swine fever and COVID-19, affecting the overall timeline and expected returns[126] Subsidiaries and Acquisitions - The company has established several new subsidiaries during the reporting period, including TianKang Pharmaceutical (Suzhou) Co., Ltd. and TianKang Biological Pharmaceutical Co., Ltd., which are now included in the consolidated scope[82] - The company has made strategic acquisitions, including Ningxia Changxin Agricultural Development Co., Ltd. and Ningxia Xinchang Logistics Co., Ltd., which are now part of the consolidated scope[82] Dividend Policy - In 2020, the company distributed cash dividends of 4.6 yuan per 10 shares, with no capital reserve transfer to share capital[163] - The cash dividend amount for 2020 was CNY 494,568,934.22, representing 28.75% of the net profit attributable to ordinary shareholders[164] - The total cash dividend (including other methods) for 2020 accounted for 100% of the distributable profit of CNY 955,000,469.25[169] - The company is in a growth phase and has significant capital expenditure plans, with a minimum cash dividend ratio of 20% during profit distribution[169] Compliance and Governance - The company has committed to maintaining independent management and compliance with relevant laws and regulations[170] - The company has not reported any significant non-operating fund occupation by controlling shareholders during the reporting period[179] - The company has engaged CITIC Securities as a sponsor for its non-public stock issuance, following the termination of the previous agreement with Great Wall Securities[185]